<DOC>
	<DOC>NCT00862472</DOC>
	<brief_summary>The purpose of the study is to demonstrate that the IOP-lowering efficacy of DuoTrav APS, dosed once-daily in the morning, is non-inferior to that of DuoTrav, dosed once-daily in the morning.</brief_summary>
	<brief_title>Safety and Efficacy Study of DuoTrav APS Versus DuoTrav</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Patients with openangle glaucoma or ocular hypertension who would benefit from a fixed combination medication, in the opinion of the investigator and who are currently on a stable treatment of IOPlowering medication VA not worse than 0.60 additional clinically relevant ocular or systemic conditions may be excluded</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)</keyword>
</DOC>